The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Seroquel XR 400mg prolonged-release tablets.

400 milligram(s) Prolonged-release tablet

AstraZeneca ABPA1019/019/009

Main Information

Trade NameSeroquel XR 400mg prolonged-release tablets.
Active SubstancesQuetiapine
Strength400 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderAstraZeneca AB
Licence NumberPA1019/019/009

Group Information

ATC CodeN05AH Diazepines, oxazepines, thiazepines and oxepines
N05AH04 quetiapine


Licence Issued15/02/2008
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0019-068-024
Interchangeable List DocumentPDF of Interchangeable List
« Back